{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:22:12Z","timestamp":1790644932319,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ygyno.2021.07.019","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T08:33:07Z","timestamp":1626683587000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database"],"prefix":"10.1016","volume":"163","author":[{"given":"Alexandre","family":"De Nonneville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Zemmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e8l\u00e8ne","family":"Costaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Classe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"De la Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Sauterey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pomel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Barranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude-Marie","family":"Savoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Guillemet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtane","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Courtinard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.07.019_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0010","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0015","series-title":"WHO classification of tumours of female reproductive organs","author":"Carcangiu","year":"2014"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2020.01.041","article-title":"Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study","volume":"223","author":"Hermens","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0025","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2019.07.012","article-title":"Molecular profiling and molecular classification of endometrioid ovarian carcinomas","volume":"154","author":"Cybulska","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2020.02.011","article-title":"An integrated molecular profile of endometrioid ovarian cancer","volume":"157","author":"Pierson","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jogc.2016.10.006","article-title":"Endometrioid carcinoma of the ovary: outcomes compared to serous carcinoma after 10 years of follow-up","volume":"39","author":"Bouchard-Fortier","year":"2017","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0050","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/annonc\/mdx525","article-title":"Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000-2013","volume":"28","author":"Oseledchyk","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023568","article-title":"The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the epidemiological strategy and medical economics (ESME)","volume":"9","author":"P\u00e9rol","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0060","article-title":"EP967 natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment","volume":"29","author":"Romeo","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0065","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/annonc\/mdw260","article-title":"Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study","volume":"27","author":"Delaloge","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0070","first-page":"93","article-title":"Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients","volume":"95","author":"Jacquet","year":"2018","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.breast.2020.11.014","article-title":"Impact of body mass index on overall survival in patients with metastatic breast cancer","volume":"55","author":"Saleh","year":"2020","journal-title":"Breast Edinb. Scotl."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","article-title":"Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers","volume":"109","author":"Chan","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0090","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1067\/S0002-9378(03)00579-9","article-title":"Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades","volume":"189","author":"Barnholtz-Sloan","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ssu.2980100107","article-title":"FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina","volume":"10","author":"Kosary","year":"1994","journal-title":"Semin. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/gyno.2000.5805","article-title":"Long-term results and prognostic factors in patients with epithelial ovarian cancer","volume":"78","author":"Brun","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/gyno.2001.6536","article-title":"Survival among U.S. women with invasive epithelial ovarian cancer","volume":"84","author":"McGuire","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.1995.1027","article-title":"The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer","volume":"56","author":"Makar","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0115","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0120","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/gyno.2001.6172","article-title":"Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study","volume":"81","author":"Akahira","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0130","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.bjc.6604299","article-title":"The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?","volume":"98","author":"Chan","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.06.049","article-title":"Natural history and outcome of mucinous carcinoma of the ovary","volume":"205","author":"Schiavone","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2017.11.018","article-title":"Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG oncology\/gynecologic oncology group ancillary data study","volume":"148","author":"Hamilton","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2017.10.032","article-title":"Who are the long-term survivors of high grade serous ovarian cancer?","volume":"148","author":"Hoppenot","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0150","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/AOG.0000000000000981","article-title":"Characteristics of long-term survivors of epithelial ovarian cancer","volume":"126","author":"Cress","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0155","first-page":"1562","article-title":"Prognostic significance of endometrioid ovarian cancer subtype: results of an international multi-institutional retrospective study","volume":"27","author":"de Nonneville","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","author":"Colombo","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0165","first-page":"313","article-title":"Gynecologic cancers associated with Lynch syndrome\/HNPCC","volume":"10","author":"Schmeler","year":"2008","journal-title":"Clin. Transl. Oncol. Off. Publ. Fed. Span Oncol. Soc. Natl. Cancer Inst. Mex."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molonc.2009.02.004","article-title":"Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management","volume":"3","author":"Lynch","year":"2009","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2014.07.100","article-title":"Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary","volume":"135","author":"Vierkoetter","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0180","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology","volume":"14","author":"Pal","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0185","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ijc.25835","article-title":"Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America","volume":"129","author":"Murphy","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.3688","article-title":"Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer","author":"Hodan","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0195","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0200","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.mayocp.2019.02.017","article-title":"Hereditary cancer syndromes-a primer on diagnosis and management: part 1: breast-ovarian cancer syndromes","volume":"94","author":"Samadder","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0205","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti\u2013programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair\u2013deficient endometrial cancer: a nonrandomized phase 1 clinical trial","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0210","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database","volume":"66","author":"M\u00f8ller","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ygyno.2021.07.019_bb0215","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0220","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0225","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0230","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0235","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0240","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.019_bb0245","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","article-title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies","volume":"13","author":"Pearce","year":"2012","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:59:35Z","timestamp":1758772775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821005813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0090825821005813"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}